Silence Therapeutics (SLN) Cash from Financing Activities (2024 - 2025)
Silence Therapeutics (SLN) reported Cash from Financing Activities of $1000.0 for Q2 2025, down 99.92% on a YoY basis from $1.2 million in Q2 2024, and down 92.86% sequentially from $14000.0 in Q1 2025.
Silence Therapeutics (SLN) Cash from Financing Activities (2024 - 2025) Analysis & Trends
Silence Therapeutics (SLN) has 2 years of Cash from Financing Activities data on file, last reported at $1000.0 in Q2 2025.
- For the quarter ending Q2 2025, Cash from Financing Activities fell 99.92% year-over-year to $1000.0; the trailing twelve-month figure through Mar 2026 stood at $1000.0 (down 99.99% YoY), and the FY2025 full-year result was $15000.0, down 99.99% from the prior year.
- Cash from Financing Activities slipped to $1000.0 in Q2 2025, from $14000.0 in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $133.0 million in Q1 2024 to a low of -$98000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 30.14 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 68.63 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 9,311.16 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -538.80 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -802.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 238.74 Mn |
| 10 | Silence Therapeutics | 1.62 Bn | 1.49 Bn | 411,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 1,000.00 |
| Jun 30, 2025 | 1,000.00 |
| Mar 31, 2025 | 14,000.00 |
| Mar 31, 2025 | 14,000.00 |
| Dec 31, 2024 | -98,000.00 |
| Dec 31, 2024 | -98,000.00 |
| Sep 30, 2024 | 7.97 Mn |
| Sep 30, 2024 | 7.97 Mn |
| Jun 30, 2024 | 1.19 Mn |
| Jun 30, 2024 | 1.19 Mn |
| Mar 31, 2024 | 133.02 Mn |
| Mar 31, 2024 | 133.02 Mn |